Nuclear Medicine Radioisotopes Market Report 2026

The nuclear medicine radioisotopes market size has grown strongly in recent years. It will grow from $8.85 billion in 2025 to $9.58 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to widespread use of technetium-99m in diagnostic imaging, growing adoption of nuclear cardiology procedures, increasing prevalence of cancer and thyroid disorders, expansion of hospital-based nuclear medicine departments, early clinical success of radioisotope-based therapies.

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include rising adoption of theranostics in oncology care, growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine in cardiology and neurology, strengthening focus on domestic radioisotope production.

The rising incidence of cardiovascular diseases is expected to drive the expansion of the nuclear medicine radioisotope market in the coming years. Cardiovascular diseases include a variety of conditions that affect the heart and blood vessels. The increase in cardiovascular disease cases is linked to sedentary lifestyles, poor dietary habits, higher obesity rates, and aging populations. Nuclear medicine radioisotopes are essential for diagnosing, evaluating, and managing cardiovascular diseases by offering detailed information on cardiac function, perfusion, and tissue viability, which are vital for accurate diagnosis and effective treatment planning. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4% from 224.4 per 100,000 in 2023. As a result, the increasing prevalence of cardiovascular diseases is driving the growth of the nuclear medicine radioisotope market.

Major companies in the nuclear medicine radioisotopes market are focusing on developing advanced solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted therapies. Next-generation theranostic radiopharmaceuticals are highly specialized radioactive agents designed to both detect and accurately treat diseases by precisely targeting specific cells within the body. For instance, in November 2025, the University of California, a US-based research university, created a completely independent Department of Nuclear Medicine & Theranostics, rather than maintaining nuclear medicine as part of a broader radiology division. This newly established department aims to accelerate the use of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and encourage innovations in theranostic treatments.

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. Through this acquisition, Telix Pharmaceuticals aimed to strengthen its nuclear medicine capabilities, optimize production processes, and broaden its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS, headquartered in Canada, provides advanced radioisotope technology and operates in the field of nuclear medicine radioisotopes.

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation.

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nuclear medicine radioisotopes market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nuclear medicine radioisotopes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the nuclear medicine radioisotopes market by increasing costs associated with importing radioisotopes, enriched materials, cyclotron components, and shielding equipment. These effects are most pronounced in regions dependent on cross-border isotope supply chains, including North America and parts of Europe. Supply disruptions and higher logistics costs have affected diagnostic and therapeutic segments, particularly short half-life isotopes. However, tariffs have also encouraged domestic isotope production, regional cyclotron investments, and supply chain localization, supporting long-term market resilience.

The nuclear medicine radioisotopes market research report is one of a series of new reports that provides nuclear medicine radioisotopes market statistics, including nuclear medicine radioisotopes industry global market size, regional shares, competitors with a nuclear medicine radioisotopes market share, detailed nuclear medicine radioisotopes market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. This nuclear medicine radioisotopes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and investigate various medical conditions. These isotopes emit radiation that can be detected and imaged with specialized equipment or can provide therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes.

The main types of nuclear medicine radioisotopes include technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), among others. Technetium-99m (Tc-99m) is a radioactive isotope widely utilized in nuclear medicine imaging procedures for the diagnosis of various medical conditions. Its uses cover areas such as oncology, cardiology, thyroid, neurology, and more, serving end users including hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.